Analysis on correlation between serum matrix metalloproteinase-12, microRNA-22 levels and clinicopathological features of patients with gastric cancer
-
摘要: 目的 分析血清基质金属蛋白酶-12(MMP-12)水平、微小RNA-22(miR-22) mRNA相对表达量对胃癌患者临床病理特征的影响。方法 选取2020年2月-2021年2月收治的90例胃癌患者为研究对象。观察患者的临床病理特征，并检测血清MMP-12水平、miR-22 mRNA相对表达量，分析血清MMP-12水平、miR-22 mRNA相对表达量对胃癌患者临床病理特征的影响。结果 肿瘤细胞转移及扩散患者、TNM分期Ⅲ~Ⅳ期患者的血清MMP-12水平高于肿瘤细胞未转移及扩散患者、TNM分期Ⅰ~Ⅱ期患者，均差异有统计学意义(P＜0.05)；miR-22 mRNA相对表达量低于肿瘤细胞未转移及扩散患者、TNM分期Ⅰ~Ⅱ期患者，均差异有统计学意义(P＜0.05)。回归分析结果显示，血清MMP-12水平、miR-22 mRNA相对表达量与胃癌患者的临床病理特征有关(P＜0.05)。绘制受试者工作特征曲线，结果显示胃癌患者血清MMP-12水平、miR-22 mRNA相对表达量评估肿瘤细胞转移、扩散和TNM高分期风险的曲线下面积均>0.70，评估价值较理想，且两者联合评估的价值最高。结论 血清MMP-12水平、miR-22 mRNA相对表达量与胃癌患者的临床病理特征具有一定的相关性。Abstract: Objective To investigate the effect of serum matrix metalloproteinase-12(MMP-12) level and relative expression of microRNA(miR) -22 mRNA on clinicopathological characteristics in patients with gastric cancer.Methods Ninety patients with gastric cancer from February 2020 to February 2021 were prospectively selected. The clinicopathological characteristics of patients was observed, the serum MMP-12 level and the relative expression of miR-22 mRNA of patients were detected, the effect of serum MMP-12 level and miR-22 mRNA relative expression on clinicopathological characteristics in patients with gastric cancer were analyzed.Results The levels of serum MMP-12 in patients with metastasis and diffusion of tumor cells and patients with stage Ⅲ-Ⅳwere higher than those in patients without metastasis and diffusion of tumor cells and patients with stageⅠ-Ⅱ, the relative expression of miR-22 mRNA was lower than that in patients without metastasis and diffusion of tumor cells and patients with stage Ⅰ-Ⅱ, the difference was statistically significant(P < 0.05); the results of regression analysis showed that the serum MMP-12 level and relative expression of miR-22 mRNA were related to the clinicopathological features of patients with gastric cancer(P < 0.05); the receiver operating curve was drawn, the area under the curve of the serum MMP-12 level and the relative expression of miR-22 mRNA in gastric cancer patients for predicting the risk of tumor cell metastasis, diffusion and high TNM staging were >0.70, the predictive value was ideal, and the joint prediction value was the best.Conclusion The serum MMP-12 level and the relative expression of miR-22 mRNA are correlated with the clinicopathological features of patients with gastric cancer.
-
Key words:
- gastric cancer /
- matrix metalloproteinase-12 /
- microRNA-22 /
- staging /
- transfer /
- differentiation
-
-
表 1 90例患者临床病理特征的分布情况
临床病理特征 例数 比例/% 分化程度 低分化 48 53.33 中高分化 30 33.33 未分化 12 13.33 肿瘤细胞转移、扩散 有 55 61.11 无 35 38.89 TNM分期 Ⅰ期 15 16.67 Ⅱ期 23 25.56 Ⅲ期 42 46.66 Ⅳ期 10 11.11 年龄/岁 ≤60 50 55.56 ＞60 40 44.44 肿瘤位置 胃小弯和胃窦 64 71.11 胃底 26 28.89 脉管侵犯 有 18 20.00 无 72 80.00 肿瘤大小/cm ≥3 15 16.67 ＜3 75 83.33 胃癌分型 腺癌 39 43.33 腺鳞癌 15 16.67 鳞状细胞癌 22 24.44 类癌 14 15.56 
下载: 导出CSV
表 2 不同临床病理特征的胃癌患者血清MMP-12、miR-22 mRNA相对表达情况
X±S，M(P25，P75) 临床病理特征 例数 MMP-12/(ng·mL-1) miR-22 mRNA相对表达量 分化程度 低分化 48 5.41±2.18 4.59±1.63 中高分化 30 5.37±2.15 4.67±1.65 未分化 12 5.29±2.11 4.52±1.60 F 0.015 0.042 P 0.985 0.959 肿瘤细胞转移、扩散 有 55 5.85(4.69，6.89) 2.20(1.95，2.73) 无 35 4.51(4.03，5.90) 2.91(2.40，3.11) U 3.493 4.110 P ＜0.001 ＜0.001 TNM分期 Ⅰ~Ⅱ期 38 4.18±1.35 5.30±1.07 Ⅲ~Ⅳ期 52 5.42±1.07 4.15±1.19 t 4.859 4.955 P ＜0.001 ＜0.001 年龄/岁 ≤60 50 4.86±1.87 4.29±1.78 >60 40 4.93±1.89 4.18±1.72 t 0.176 0.296 P 0.861 0.768 肿瘤位置 胃小弯和胃窦 64 5.17±2.14 4.59±2.03 胃底 26 5.09±2.01 4.37±1.85 t 0.156 0.478 P 0.876 0.634 脉管侵犯 有 18 5.36±2.11 4.69±1.90 无 72 5.41±2.15 4.65±1.87 t 0.089 0.081 P 0.930 0.936 肿瘤大小/cm ≥3 15 5.29±2.05 4.24±1.70 ＜3 75 5.22±2.03 4.18±1.67 t 0.122 0.127 P 0.903 0.900 胃癌分型 腺癌 39 5.07±2.06 4.45±1.84 腺鳞癌 15 4.89±1.94 4.33±1.72 鳞状细胞癌 22 4.71±1.82 4.58±1.89 类癌 14 4.93±1.99 4.29±1.78 F 0.159 0.093 P 0.924 0.964
下载: 导出CSV
表 3 血清MMP-12、miR-22 mRNA相对表达量对胃癌患者临床病理特征影响的回归分析结果
变量 β SE Wald χ2 P OR 95%CI 上限 下限 肿瘤细胞转移、扩散 常量 2.068 1.700 1.481 0.224 MMP-12 0.630 0.212 8.794 0.003 1.877 1.238 2.845 miR-22 mRNA相对表达量 -1.942 0.547 12.593 ＜0.001 0.143 0.049 0.419 Ⅲ~Ⅳ期 常量 0.080 1.578 0.003 0.960 MMP-12 0.850 0.243 12.218 ＜0.001 2.341 1.453 3.771 miR-22 mRNA相对表达量 -0.944 0.266 12.536 ＜0.001 0.389 0.231 0.565
下载: 导出CSV
表 4 血清MMP-12、miR-22 mRNA相对表达量评估胃癌患者临床病理特征风险的效能分析结果
变量 AUC AUC的95%CI SE P cut-off值 特异度 灵敏度 约登指数 肿瘤细胞转移、扩散 MMP-12 0.719 0.611~0.827 0.055 ＜0.001 4.535 ng/mL 0.514 0.818 0.332 miR-22 mRNA相对表达量 0.758 0.657~0.859 0.052 ＜0.001 3.005 0.571 0.855 0.426 联合 0.804 0.714~0.894 0.046 ＜0.001 0.600 0.873 0.473 Ⅲ~Ⅳ期 MMP-12 0.758 0.661~0.855 0.050 ＜0.001 4.325 ng/mL 0.538 0.816 0.354 miR-22 mRNA相对表达量 0.757 0.657~0.858 0.051 ＜0.001 5.505 0.519 0.842 0.361 联合 0.816 0.759~0.919 0.041 ＜0.001 0.692 0.895 0.587
下载: 导出CSV
-
[1] Cheung KS, Chan EW, Wong AYS, et al. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study[J]. Gut, 2018, 67(1): 28-35. doi: 10.1136/gutjnl-2017-314605
[2] Raimondi A, Nichetti F, Peverelli G, et al. Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies[J]. Pharmacogenomics, 2018, 19(13): 1047-1068. doi: 10.2217/pgs-2018-0077
[3] Lian MJ, Zhang CX, Zhang DD, et al. The association of five preoperative serum tumor markers and pathological features in patients with breast cancer[J]. J Clin Lab Anal, 2019, 33(5): e22875.
[4] 王宝菊, 冯振博. 基质金属蛋白酶-12在肝细胞肝癌中的表达及临床意义[J]. 广西医科大学学报, 2021, 38(3): 556-560. doi: 10.16190/j.cnki.45-1211/r.2021.03.022
[5] Hung WY, Li WJ, Cheng GZ, et al. Blocking MMP-12-modulated epithelial-mesenchymal transition by repurposing penfluridol restrains lung adenocarcinoma metastasis via uPA/uPAR/TGF-β/Akt pathway[J]. Cell Oncol, 2021, 44(5): 1087-1103. doi: 10.1007/s13402-021-00620-1
[6] Zhang CP, Hao YL, Sun YY, et al. Quercetin suppresses the tumorigenesis of oral squamous cell carcinoma by regulating microRNA-22/WNT1/β-catenin axis[J]. J Pharmacol Sci, 2019, 140(2): 128-136. doi: 10.1016/j.jphs.2019.03.005
[7] 王媛媛, 桂百卉. HOXC-AS3和微小RNA-154在结直肠癌组织中的表达及相关性[J]. 中国中西医结合消化杂志, 2021, 29(11): 791-795. doi: 10.3969/j.issn.1671-038X.2021.11.008 http://zxpw.cbpt.cnki.net/WKD2/WebPublication/paperDigest.aspx?paperID=6c8c3da5-853e-467b-b143-c40ae7e4b337
[8] Feng XD, Luo QQ, Wang H, et al. MicroRNA-22 suppresses cell proliferation, migration and invasion in oral squamous cell carcinoma by targeting NLRP3[J]. J Cell Physiol, 2018, 233(9): 6705-6713. doi: 10.1002/jcp.26331
[9] 中华人民共和国国家卫生和计划生育委员会. 胃癌规范化诊疗指南(试行)[J]. 慢性病学杂志, 2013, 5(10): 47-51. https://www.cnki.com.cn/Article/CJFDTOTAL-YXQY201308011.htm
[10] German AI, Wittekind C. 2010 TNM system: on the 7th edition of TNM classification of malignant tumors[J]. Pathologe, 2010, 31(5): 331-332. doi: 10.1007/s00292-010-1349-3
[11] 潘婷婷, 陈威佐, 关泉林. 胃癌靶向治疗的研究进展[J]. 中国肿瘤临床, 2018, 45(4): 209-213. doi: 10.3969/j.issn.1000-8179.2018.04.546
[12] 张峰, 张媛, 孙立新, 等. H226细胞和肺癌及其淋巴结转移组织CPA4表达以及生物学功能研究[J]. 中华肿瘤防治杂志, 2019, 26(6): 366-372. doi: 10.16073/j.cnki.cjcpt.2019.06.001
[13] 韩晶, 王贵英, 张难, 等. 肿瘤部位及临床病理特征对不同TNM分期行结直肠癌根治性切除术患者预后的影响研究[J]. 中国全科医学, 2020, 23(18): 2275-2283. doi: 10.12114/j.issn.1007-9572.2020.00.336
[14] 吴伟东, 罗磊, 丁锋. 肺癌相关基质金属蛋白酶研究进展[J]. 山东医药, 2018, 58(13): 93-96. doi: 10.3969/j.issn.1002-266X.2018.13.031
[15] Huang YM, Zhang B, Haneke H, et al. Glial cell line-derived neurotrophic factor increases matrix metallopeptidase 9 and 14 expression in microglia and promotes microglia-mediated glioma progression[J]. J Neurosci Res, 2021, 99(4): 1048-1063. doi: 10.1002/jnr.24768
[16] 赵志强, 马福林, 陈敏学, 等. MMP-28的特性及其在肿瘤发生发展中的作用[J]. 生命科学研究, 2020, 24(5): 410-414. doi: 10.16605/j.cnki.1007-7847.2020.05.009
[17] Guan CY, Xiao YD, Li K, et al. MMP-12 regulates proliferation of mouse macrophages via the ERK/P38 MAPK pathways during inflammation[J]. Exp Cell Res, 2019, 378(2): 182-190. doi: 10.1016/j.yexcr.2019.03.018
[18] 吴越, 吕帆真, 李政, 等. 基质金属蛋白酶12与肿瘤关系的研究进展[J]. 现代肿瘤医学, 2020, 28(19): 3438-3441. doi: 10.3969/j.issn.1672-4992.2020.19.035
[19] Yang HJ, Zhang CT, Wu JY, et al. Association of matrix metalloproteinase-12 polymorphisms with chronic obstructive pulmonary disease risk: A protocol for systematic review and meta analysis[J]. Medicine(Baltimore), 2020, 99(31): e21543.
[20] Yang F, Chen QS, He SP, et al. miR-22 Is a Novel Mediator of Vascular Smooth Muscle Cell Phenotypic Modulation and Neointima Formation[J]. Circulation, 2018, 137(17): 1824-1841. doi: 10.1161/CIRCULATIONAHA.117.027799
[21] Lone SN, Maqbool R, Parray FQ, et al. Triose-phosphate isomerase is a novel target of miR-22 and miR-28, with implications in tumorigenesis[J]. J Cell Physiol, 2018, 233(11): 8919-8929. doi: 10.1002/jcp.26821
[22] Li Y, Gu YJ, Tang N, et al. miR-22-Notch Signaling Pathway Is Involved in the Regulation of the Apoptosis and Autophagy in Human Ovarian Cancer Cells[J]. Biol Pharm Bull, 2018, 41(8): 1237-1242. doi: 10.1248/bpb.b18-00084
[23] 尹纪来, 高飞, 李浩, 等. 胆囊癌患者血清MMP-7、MMP-10、MMP-12水平变化及其与临床病理特征和预后的关系[J]. 山东医药, 2019, 59(10): 63-65. doi: 10.3969/j.issn.1002-266X.2019.10.017
[24] 郭海州, 安生花, 林明哲, 等. MMP-12, VEGF-D和VEGFR-3在胃低分化腺癌中的表达及意义[J]. 中国老年学杂志, 2019, 39(20): 4961-4965. doi: 10.3969/j.issn.1005-9202.2019.20.026
[25] 胡乃军, 王海龙. 胃腺癌组织中MMP-11、MMP-12和VEGF-D的表达及临床意义[J]. 陕西医学杂志, 2019, 48(5): 554-556. doi: 10.3969/j.issn.1000-7377.2019.05.003
[26] 王帅, 高丽洁, 王淑芳, 等. 胃癌患者血清MMP-2, MMP-10, MMP-12表达及临床意义[J]. 疑难病杂志, 2020, 19(12): 1225-1228. doi: 10.3969/j.issn.1671-6450.2020.12.010
[27] Sun RF, Liu ZG, Han L, et al. miR-22 and miR-214 targeting BCL9 L inhibit proliferation, metastasis, and epithelial-mesenchymal transition by down-regulating Wnt signaling in colon cancer[J]. FASEB J, 2019, 33(4): 5411-5424. doi: 10.1096/fj.201801798RR
[28] 蒋如如, 赵川. miR-22与肿瘤[J]. 中国生物制品学杂志, 2020, 33(7): 832-836. https://www.cnki.com.cn/Article/CJFDTOTAL-SWZP202007019.htm
[29] 杨焕丽, 贾泽博, 梁晓萍, 等. 胃癌患者血清miR-22、miR-20a的水平变化及意义[J]. 山东医药, 2020, 60(31): 67-70. doi: 10.3969/j.issn.1002-266X.2020.31.017
[30] 曹锦涛, 陈刘成, 李然, 等. RNA干扰CD151基因对子宫颈癌细胞增殖和迁移的影响[J]. 临床与实验病理学杂志, 2021, 37(7): 803-809. https://www.cnki.com.cn/Article/CJFDTOTAL-LSBL202107011.htm
[31] 程龙, 王卉. CD151基因干扰对人肺腺癌A549细胞侵袭与转移能力和裸鼠肺转移成瘤的影响[J]. 中国临床药理学杂志, 2020, 36(15): 2257-2260. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ202015028.htm
[32] 王珣, 张鹏, 刘智明, 等. MiR-22靶向调控CD151促进胃癌血管新生的机制研究[J]. 中华全科医学, 2018, 16(12): 1984-1988. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201812010.htm
-
图(2)
表(4)
计量
- 文章访问数: 349
- PDF下载数: 120
- 施引文献: 0